ETF Data
XBI ETF Data
Fund Profile · Snapshot Metrics · Exposure · Technicals · Risk
XBIState Street SPDR S&P Biotech ETF
Financial Services / Asset Management
Low Priority
Above Peers
Latest quote
- Momentum70
- Value48
- Quality65
- Risk resilience56
- Sentiment—
ETF Data Overview
ETF pages show fund-native profile, cost, size, liquidity, exposure, technical, and risk evidence.
ETF Snapshot Data
Updated Oct 30, 2026.
| Field | Value |
|---|---|
| Fund name | State Street SPDR S&P Biotech ETF |
| Issuer | SPDR |
| Asset class | Equity |
| Primary exposure | Healthcare (99.28%) |
| Domicile | US |
| Inception date | Jan 31, 2006 |
| NAV currency | USD |
| CUSIP | — |
| ISIN | US78464A8707 |
| Field | Value |
|---|---|
| Price | $155.98 |
| Fund size | $8.16B |
| Expense ratio | 0.35% |
| Holdings count | 156 |
| NAV | $157.82 |
| Average volume | 9M |
| Distribution yield | 0.35% |
| AIQ Score | 60/100 |
ETF Holdings
Reported holdings from the latest ETF holder snapshot.
- MRNAMODERNA INC2.87%
- TWSTTWIST BIOSCIENCE CORP1.81%
- HALOHALOZYME THERAPEUTICS INC1.47%
- NTRANATERA INC1.46%
- KYMRKYMERA THERAPEUTICS INC1.45%
- Rest of fund90.95%
| Symbol | Holding | Weight | Market value |
|---|---|---|---|
| MRNA | MODERNA INC | 2.87% | $303.43M |
| TWST | TWIST BIOSCIENCE CORP | 1.81% | $191.2M |
| HALO | HALOZYME THERAPEUTICS INC | 1.47% | $155.02M |
| NTRA | NATERA INC | 1.46% | $153.9M |
| KYMR | KYMERA THERAPEUTICS INC | 1.45% | $152.77M |
| TVTX | TRAVERE THERAPEUTICS INC | 1.40% | $147.54M |
| ROIV | ROIVANT SCIENCES LTD | 1.39% | $147.2M |
| ORKA | ORUKA THERAPEUTICS INC | 1.38% | $146.21M |
| RVMD | REVOLUTION MEDICINES INC | 1.36% | $144.06M |
| PRAX | PRAXIS PRECISION MEDICINES I | 1.36% | $143.69M |
| INSM | INSMED INC | 1.34% | $141.5M |
| PTGX | PROTAGONIST THERAPEUTICS INC | 1.33% | $140.18M |
| DNTH | DIANTHUS THERAPEUTICS INC | 1.31% | $138.04M |
| REGN | REGENERON PHARMACEUTICALS | 1.27% | $134.7M |
| CGON | CG ONCOLOGY INC | 1.27% | $133.91M |
| PCVX | VAXCYTE INC | 1.25% | $132.46M |
| SMMT | SUMMIT THERAPEUTICS INC | 1.23% | $129.98M |
| SRRK | SCHOLAR ROCK HOLDING CORP | 1.22% | $128.97M |
| ERAS | ERASCA INC | 1.16% | $122.47M |
| RLAY | RELAY THERAPEUTICS INC | 1.16% | $122.17M |
| RYTM | RHYTHM PHARMACEUTICALS INC | 1.15% | $121.79M |
| GILD | GILEAD SCIENCES INC | 1.15% | $121.75M |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | 1.15% | $121.35M |
| TGTX | TG THERAPEUTICS INC | 1.15% | $121.36M |
| VRTX | VERTEX PHARMACEUTICALS INC | 1.14% | $120.63M |
ETF Exposure
Sector and country composition fields from ETF snapshots where available.
| Field | Value |
|---|---|
| Financial Services | 0.72% |
| Healthcare | 99.28% |
| Field | Value |
|---|---|
| Ireland | 0.08% |
| Switzerland | 1.43% |
| United States | 96.65% |
| China | 0.05% |
| Netherlands | 0.50% |
| United Kingdom | 1.29% |
Institutional Holder Snapshot
Latest downstream filing-reported holders and share-count changes for this ETF.
No downstream institutional holder rows are available for this ETF yet.
Current ETF Metrics
ETF-native fields sit beside technical and risk readings for deeper research.
| Metric | Value |
|---|---|
| Expense Ratio | 0.35% |
| Fund Size | $8.16B |
| NAV | $157.82 |
| Average Volume | 9M |
| Beta | 1.1 |
| 52-week high | $169.89 |
| 52-week low | $106.30 |
As of Oct 30, 2026
| Metric | Value |
|---|---|
| Close | $155.98 |
| Volume | 10.87M |
| RSI (14) | 55.53 |
| MACD | -0.17 |
| MACD signal | -1.35 |
| MACD histogram | 1.18 |
| ADX (14) | 14.31 |
| SMA (50) | $156.75 |
| SMA (200) | $141.50 |
| ATR (14) | $4.35 |
| Historical volatility (annualized) | 33.54% |
| Volume (20-day average) | 9.89M |
As of Oct 30, 2026
| Metric | Value |
|---|---|
| Resilience score | 56/100 |
| Beta | 1.1 |
| Annual volatility | 29.06% |
| Max Drawdown | -14.88% |
| Sharpe Ratio | 1.23 |
| VaR (95%, 1-day) | -2.96% |
As of Oct 30, 2026
Additional ETF Metrics
Expanded ETF structure fields appear here when the entitlement and source coverage allow them.
No additional ETF structure metrics are available.
Related Links
XBI ETF Data FAQ
What data matters most for XBI ETF?
XBI ETF data should be read through fund-native fields such as expense ratio, fund size, NAV, holdings, exposure, distribution yield, liquidity, technicals, and risk measures.
Why does XBI not show revenue or EPS?
XBI is an ETF, not an operating company. It does not have company revenue, EPS, margins, or free cash flow; those belong to the underlying holdings, not the fund wrapper.
What does XBI's expense ratio show?
XBI's expense ratio is the annual fund cost when available. It should be compared with fund strategy, income profile, liquidity, and exposure.
How should investors read XBI's holdings data?
XBI's holdings data shows what the fund owns and how concentrated the portfolio is. Holdings weights and sector exposure explain much of the fund's risk and return behavior.
What does XBI's distribution yield mean?
XBI's distribution yield describes the income paid by the ETF over the measured period. It should be read with payout history, fund strategy, fees, and price risk.
Why can ETF profile fields be unavailable?
ETF profile fields can be unavailable when the provider snapshot, serving layer, or entitlement path has not published that field for XBI. Missing ETF fields should remain blank rather than be inferred from stock fundamentals.